Investor TCG Crossover GP I, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by TCG Crossover GP I, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-14 13G/A CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) 6,437,497 3,858,000
2025-05-15 13G/A JBIO / Jade Biosciences, Inc. 64,023
2025-05-15 13G/A CGON / CG Oncology, Inc. 3,570,206 3,670,206
2025-03-06 13G TYRA / Tyra Biosciences, Inc. 2,898,103
2025-02-14 13G/A ANTX / AN2 Therapeutics, Inc. 1,555,118 0
2025-02-14 13G UPB / Upstream Bio, Inc. 2,801,763
2024-11-13 13G/A ANTX / AN2 Therapeutics, Inc. 2,678,209 1,555,118
2024-04-19 13G ABVX / ABIVAX Société Anonyme - Depositary Receipt (Common Stock) 6,056,596
2024-04-01 13D/A KALV / KalVista Pharmaceuticals, Inc. 2,700,840 1,345,826
2024-02-20 13D/A KALV / KalVista Pharmaceuticals, Inc. 3,408,081 2,700,840
2024-02-13 13G/A CBAY / CymaBay Therapeutics, Inc. 5,905,400 0
2024-02-09 13G CGON / CG Oncology, Inc. 3,570,206
2024-02-09 13G AVTE / Aerovate Therapeutics, Inc. 2,201,274
2024-02-09 13G/A ANTX / AN2 Therapeutics, Inc. 1,289,320 2,678,209
2024-02-09 13G/A TSHA / Taysha Gene Therapies, Inc. 11,111,111 2,912,861
2024-02-09 13G/A COGT / Cogent Biosciences, Inc. 3,631,042 5,631,042
2024-02-09 13G TRML / Tourmaline Bio, Inc. 1,477,593
2023-08-28 13G CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock) 6,437,497
2023-08-25 13G TSHA / Taysha Gene Therapies, Inc. 11,111,111
2023-07-25 13G ANTX / AN2 Therapeutics, Inc. 1,289,320
2023-07-25 13G ICVX / Icosavax, Inc. 3,703,704
2023-07-25 13G SVRA / Savara Inc. 10,000,000
2023-02-14 13G/A COGT / Cogent Biosciences, Inc. 3,631,042
2023-02-14 13G/A CBAY / CymaBay Therapeutics, Inc. 5,905,400
2023-02-14 13G/A SLNCF / Silence Therapeutics plc 6,314,625
2023-02-14 13G/A VRDN / Viridian Therapeutics, Inc. 983,610
2023-01-09 13D KALV / KalVista Pharmaceuticals, Inc. 3,408,081